MarginsXMarginsX
Home › Markets › Health Care › HALO

Halozyme Therapeutics Inc. (HALO)

HALO trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$96.50
-3.76% on the day
Market cap
$11.0B
Large cap
Revenue · 2025
$1.4B
+37.6% on 2024
Net income · 2025
$316.9M
22.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/0001159036-26-000024-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerHALO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001159036
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$1.4B
Net income$316.9M
Operating income$469.0M
Net margin22.7%
Operating margin33.6%
Revenue growth+37.6%
Cash$133.8M
Total assets$2.5B
P/E (computed)34.7×
P/S (computed)7.9×

Warning signs

Cash runway
Cash-flow positive
$1.0B cash at September 30, 2026
Share count, 1 year
-3.1%
2025-10-27 to 2026-10-31 · -13.7% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$45.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$1.0B cash; operating cash flow $224.6M a quarter.Report 2026-09-30
Shares outstanding114,010,000 (2026-10-31); 117,597,000 a year earlier; 132,098,110 three years earlier.Cover page 2026-10-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Diego, California, United StatesPCAOB Form AP 2026-03-02
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $45.7M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$493.0M$247.0M$258.3M$1.0B$3.3B$1.8B10-Q 2026-11-05
Q2 2026
2026-06-30
$481.0M$229.9M$240.9M$163.1M$2.1B$1.7B10-Q 2026-08-06
Q1 2026
2026-03-31
$376.7M$150.0M$180.1M$309.7M$2.1B$1.5B10-Q 2026-05-11
Q4 2025
2025-12-31
$451.8M-$141.6M$219.0M$133.8M$2.1B$1.4B10-K 2026-02-17
Q3 2025
2025-09-30
$354.3M$175.2M$178.6M$419.7M$1.5B$1.2B10-Q 2026-11-05
Q2 2025
2025-06-30
$325.7M$165.2M$99.7M$61.9M$1.5B$1.2B10-Q 2026-08-06
Q1 2025
2025-03-31
$264.9M$118.1M$154.2M$176.3M$1.5B$1.1B10-Q 2026-05-11
Q4 2024
2024-12-31
$298.0M$137.0M$178.5M$115.8M$1.5B$1.0B10-K 2026-02-17

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52017-05-19
Latest annual report10-K2026-02-17
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-03-23

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-3.2%
1 month-8.5%
3 months-0.4%
Year to date+49.0%
1 year+40.8%
From 52-week high-23.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
KYMRKymera Therapeutics Inc.$125.85-1.35%$10.7B
TECHBio-Techne Corp$72.79-0.01%$11.4B
RGENRepligen Corporation$162.78-2.99%$10.4B
QGENQiagen N.V. Common Shares$49.81-0.16%$10.3B
PCVXVaxcyte Inc.$61.61-2.78%$9.8B
KRYSKrystal Biotech Inc.$297.90-2.40%$8.8B
CGONCG Oncology Inc.$84.78+13.95%$7.6B
EXELExelixis Inc.$67.10-2.75%$16.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier